A Phase 3 study has found that patients with Sickle Cell Disease (SCD) who took a daily dose of the novel drug voxelotor had less anemia and made healthier red blood cells than patients receiving a placebo.
Research identifies enzymes produced by two different bacterial species that work together to digest L-Dopa in the human gut. Blocking one of these bacterial enzymes could significantly boost the drug’s efficacy in these patients.
An international study may offer hope to people with a rare and debilitating genetic disorder, PKAN, as well as a potentially new approach to treat other neurodegenerative disorders, such as Alzheimer’s, Parkinson’s disease and multiple sclerosis.
Two-day symposium will bring together scientists from a variety of disciplines to discuss emerging trends in diseases such as Lyme, malaria, dengue, Zika and others that are transmitted by mosquitos, ticks, flies and other arthropod vectors.